The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Published version of a preprint
Abstract
It is generally thought that the anticancer efficacy of antibody–drug conjugates (ADC) relies on their internalization by cancer cells. However, recent work on an ADC that targets fibronectin in the tumor microenvironment suggests this may not be necessary. The alternatively spliced extra domains A and B (EDA and EDB) of fibronectin offer appealing targets for ADC development, because the antigen is strongly expressed in many solid human tumors and nearly undetectable in normal tissues except for the female reproductive system. In this study, we describe the properties of a set of ADCs based on an antibody targeting the alternatively spliced EDA of fibronectin coupled to one of a set of potent cytotoxic drugs (DM1 or one of two duocarmycin derivatives). The DM1 conjugate SIP(F8)-SS-DM1 mediated potent antitumor activity in mice bearing DM1-sensitive F9 tumors but not DM1-insensitive CT26 tumors. Quantitative biodistribution studies and microscopic analyses confirmed a preferential accumulation of SIP(F8)-SS-DM1 in the subendothelial extracellular matrix of tumors, similar to the pattern observed for unmodified antibody. Notably, we found that treatments were well tolerated at efficacious doses that were fully curative and compatible with pharmaceutical development. Our findings offer a preclinical proof-of-concept for curative ADC targeting the tumor microenvironment that do not rely upon antigen internalization. Cancer Res; 74(9); 2569–78. ©2014 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
In the citing paper
“They bind to cell surface receptors that are upregulated by mutant RAS and exhibit potent antitumor activity, demonstrating their efficacy in targeting undruggable proteins outside the cell.645–649”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [648]
Citations
Cites
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs
Chari, R. V. J. (2007) · Accounts of Chemical Research · doi:10.1021/ar700108g · Cited by 819
Senter, P. D., & Sievers, E. L. (2012) · Nature Biotechnology · doi:10.1038/nbt.2289 · Cited by 767
Neri, D., & Bicknell, R. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1627 · Cited by 601
Self-citationJunttila, T. T., Li, G., Parsons, K. L., Phillips, G. D. L., & Sliwkowski, M. X. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 544
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Tumor Infarction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature
Huang, X., Molema, G., King, S., Watkins, L. R., Edgington, T. S., & Thorpe, P. E. (1997) · Science · doi:10.1126/science.275.5299.547 · Cited by 477
Design and Use of a Phage Display Library
Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., & Neri, D. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.34.21769 · Cited by 423
Self-citationPotent antibody drug conjugates for cancer therapy
Senter, P. D. (2009) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2009.03.023 · Cited by 403
Borsi, L., Balza, E., Bestagno, M., Castellani, P., Carnemolla, B., Biro, A., Leprini, A., Sepúlveda, J., Burrone, Ó. R., Neri, D., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10662 · Cited by 354
Self-citation
Cited by
Sorted by citations
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
WICKI, A. N., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,962
Advances in Chemical Protein Modification
Boutureira, O., & Bernardes, G. J. L. (2015) · Chemical Reviews · doi:10.1021/cr500399p · Cited by 1,137
Self-citationCleavable linkers in antibody–drug conjugates
Bargh, J. D., Isidro‐Llobet, A., Parker, J. S., & Spring, D. R. (2019) · Chemical Society Reviews · doi:10.1039/c8cs00676h · Cited by 668
Srinivasarao, M., & Low, P. S. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00013 · Cited by 624
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 561
Antibody-drug conjugates—an emerging class of cancer treatment
Diamantis, N., & Banerji, U. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.435 · Cited by 526
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Antibody–Drug Conjugates: The Last Decade
Joubert, N., Beck, A., Dumontet, C., & Denevault‐Sabourin, C. (2020) · Pharmaceuticals · doi:10.3390/ph13090245 · Cited by 380
Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A. B., Wessels, H. J. C. T., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03880-y · Cited by 280
Rossin, R., van Duijnhoven, S. M. J., ten Hoeve, W., Janssen, H. M., Kleijn, L. H. J., Hoeben, F. J. M., Versteegen, R. M., & Robillard, M. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00231 · Cited by 249
Wichert, M., Krall, N., Decurtins, W., Franzini, R. M., Pretto, F., Schneider, P., Neri, D., & Scheuermann, J. (2015) · Nature Chemistry · doi:10.1038/nchem.2158 · Cited by 217
Self-citationTargeting cancer with antibody-drug conjugates: Promises and challenges
Dean, A. Q., Luo, S., Twomey, J. D., & Zhang, B. (2021) · mAbs · doi:10.1080/19420862.2021.1951427 · Cited by 195
A comprehensive overview on antibody-drug conjugates: from the conceptualization to cancer therapy
Riccardi, F., Bo, M. D., Macor, P., & Toffoli, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1274088 · Cited by 207
Casi, G., & Neri, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00457 · Cited by 193
Self-citationHoffmann, R. M., Coumbe, B. G. T., Josephs, D. H., Mele, S., Ilieva, K. M., Cheung, A., Tutt, A. N. J., Spicer, J. F., Thurston, D. E., Crescioli, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1395127 · Cited by 197
Advances in antibody–drug conjugates: A new era of targeted cancer therapy
Sau, S., Alsaab, H. O., Kashaw, S. K., Tatiparti, K., & Iyer, A. K. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.05.011 · Cited by 179
Mechanisms of action of therapeutic antibodies for cancer
Redman, J. M., Hill, E., Aldeghaither, D. S., & Weiner, L. M. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.04.002 · Cited by 179
Construction of homogeneous antibody–drug conjugates using site-selective protein chemistry
Akkapeddi, P., Azizi, S., Freedy, A. M., Cal, P. M. S. D., Góis, P. M. P., & Bernardes, G. J. L. (2016) · Chemical Science · doi:10.1039/c6sc00170j · Cited by 155
Self-citationCazzamalli, S., Corso, A. D., Widmayer, F., & Neri, D. (2018) · Journal of the American Chemical Society · doi:10.1021/jacs.7b13361 · Cited by 153
Self-citationEvolving Strategies for Target Selection for Antibody-Drug Conjugates
Damelin, M. I., Zhong, W., Myers, J. S., & Sapra, P. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1624-3 · Cited by 155
Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics
Kim, E. G., & Kim, K. M. (2015) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2015.116 · Cited by 151
Current methods for the synthesis of homogeneous antibody–drug conjugates
Sochaj, A. M., Świderska, K. W., & Otlewski, J. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.001 · Cited by 142
Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates
Pillow, T. H., Sadowsky, J., Zhang, D., Yu, S., Rosario, G. D., Xu, K., He, J., Bhakta, S., Ohri, R. V., Kozak, K. R., et al. (2016) · Chemical Science · doi:10.1039/c6sc01831a · Cited by 145
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
Singh, A. P., Sharma, S., & Shah, D. K. (2016) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-016-9495-8 · Cited by 139
Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A., & Neri, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30569 · Cited by 124
Self-citationCilliers, C., Guo, H., Liao, J., Christodolu, N., & Thurber, G. M. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9940-z · Cited by 121
Chemotherapeutic drug delivery by tumoral extracellular matrix targeting
Raavé, R., van Kuppevelt, T. H., & Daamen, W. F. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.029 · Cited by 106
Non-internalising antibody–drug conjugates
Ashman, N., Bargh, J. D., & Spring, D. R. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00446a · Cited by 94
Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
Deonarain, M. P., Yahioglu, G., Stamati, I., Pomowski, A., Clarke, J., Edwards, B. M., Diez-Posada, S., & Stewart, A. (2018) · Antibodies · doi:10.3390/antib7020016 · Cited by 94
Corso, A. D., Cazzamalli, S., Gébleux, R., Mattarella, M., & Neri, D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00304 · Cited by 92
Self-citationCazzamalli, S., Corso, A. D., & Neri, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.023 · Cited by 88
Self-citationMaass, K. F., Kulkarni, C., Betts, A. M., & Wittrup, K. D. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9892-3 · Cited by 85
Joubert, N., Denevault‐Sabourin, C., Bryden, F., & Viaud‐Massuard, M. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.049 · Cited by 84
Richards, D. A. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.10.005 · Cited by 83
Cazzamalli, S., Ziffels, B., Widmayer, F., Murer, P., Pellegrini, G., Pretto, F., Wulhfard, S., & Neri, D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3457 · Cited by 82
Self-citationKrall, N., Pretto, F., & Neri, D. (2014) · Chemical Science · doi:10.1039/c4sc00685b · Cited by 78
Self-citationDal Corso, A., Gébleux, R., Murer, P., Soltermann, A., & Neri, D. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.040 · Cited by 75
Self-citationKhera, E., & Thurber, G. M. (2018) · BioDrugs · doi:10.1007/s40259-018-0302-5 · Cited by 72
Patel, T. K., Adhikari, N., Amin, S. A., Biswas, S., Jha, T., & Ghosh, B. (2021) · New Journal of Chemistry · doi:10.1039/d0nj04134c · Cited by 68
Lin, F., Yin, S., Zhang, Z., Yu, Y., Fang, H., Liang, Z., Zhu, R., Zhou, H., Li, J., Cao, K., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.016 · Cited by 72
Emerging formats for next-generation antibody drug conjugates
Deonarain, M. P., Yahioglu, G., Stamati, I., & Marklew, J. S. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1025049 · Cited by 67
Antibody-drug conjugates: Current status and future perspectives
Gébleux, R., & Casi, G. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.07.012 · Cited by 66
Self-citationAntibodies and associates: Partners in targeted drug delivery
Kennedy, P. J., Oliveíra, C., Granja, P. L., & Sarmento, B. F. C. C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.004 · Cited by 69
Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
Theocharopoulos, C., Lialios, P., Samarkos, M., Gogas, H. J., & Ziogas, D. C. (2021) · Vaccines · doi:10.3390/vaccines9101111 · Cited by 69
Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery
Lingasamy, P., Tobi, A., Haugas, M., Hunt, H., Paiste, P., Asser, T., Rätsep, T., Kotamraju, V. R., Bjerkvig, R., & Teesalu, T. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119373 · Cited by 65
Gébleux, R., Wulhfard, S., Casi, G., & Neri, D. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0480 · Cited by 61
Self-citationWu, M., Huang, W., Yang, N., & Liu, Y. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00347-1 · Cited by 59
Cazzamalli, S., Corso, A. D., & Neri, D. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0283 · Cited by 60
Self-citationSadowsky, J., Pillow, T. H., Chen, J., Fan, F., He, C., Wang, Y., Yan, G., Yao, H., Xu, Z., Martin, S. A., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00258 · Cited by 61
Hooper, A. T., Marquette, K., Chang, C.-P. B., Golas, J., Jain, S., Lam, M., Guffroy, M., Leal, M., Falahatpisheh, H., Mathur, D., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0099 · Cited by 54
Self-citationThe Next Generation of Antibody Drug Conjugates
Mack, F. A., Ritchie, M. F., & Sapra, P. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.08.001 · Cited by 50
Secreted Gal-3BP is a novel promising target for non-internalizing Antibody–Drug Conjugates
Giansanti, F., Capone, E., Ponziani, S., Piccolo, E., Gentile, R., Lamolinara, A., Campli, A. D., Sallese, M., Iacobelli, V., Cimini, A., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.018 · Cited by 46
New Technologies Bloom Together for Bettering Cancer Drug Conjugates
Jin, Y., Zakeri, S. E., Bahal, R., & Wiemer, A. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000499 · Cited by 42
Nielsen, C., van Putten, S. M., Lund, I. K., Melander, M. C., Nørregaard, K. S., Jürgensen, H. J., Reckzeh, K., Christensen, K. R., Ingvarsen, S., Gårdsvoll, H., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17883 · Cited by 40
Prodrugs as drug delivery system in oncology
Delahousse, J., Skarbek, C., & Paci, A. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03906-2 · Cited by 40
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them
Ojaimi, Y. A., Blin, T., Lamamy, J., Gracia, M., Pitiot, A., Denevault‐Sabourin, C., Joubert, N., Pouget, J., Gouilleux‐Gruart, V., Heuzé‐Vourc'h, N., et al. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108022 · Cited by 43
A Chemically Defined Trifunctional Antibody–Cytokine–Drug Conjugate with Potent Antitumor Activity
List, T., Casi, G., & Neri, D. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0599 · Cited by 40
Self-citationDias, A. R. M., Bodero, L., Martins, A., Arosio, D., Gazzola, S., Belvisi, L., Pignataro, L., Steinkühler, C., Corso, A. D., Gennari, C., et al. (2019) · ChemMedChem · doi:10.1002/cmdc.201900049 · Cited by 37
Noninternalizing Targeted Cytotoxics for Cancer Therapy
Casi, G., & Neri, D. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500798y · Cited by 35
Self-citationGallo, F., Korsak, B., Müller, C., Hechler, T., Yanakieva, D., Avrutina, O., Kolmar, H., & Pahl, A. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00003 · Cited by 35
Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies
Venetz, D., Hess, C., Lin, C., Aebi, M., & Neri, D. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1416694112 · Cited by 33
Self-citationCazzamalli, S., Figueras, E., Pethő, L., Borbély, A., Steinkühler, C., Neri, D., & Sewald, N. (2018) · ACS Omega · doi:10.1021/acsomega.8b02350 · Cited by 33
Self-citationDias, A. R. M., Pina, A., Dean, A., Lerchen, H., Caruso, M., Gasparri, F., Fraietta, I., Troiani, S., Arosio, D., Belvisi, L., et al. (2018) · Chemistry - A European Journal · doi:10.1002/chem.201805447 · Cited by 33
Tackling solid tumour therapy with small-format drug conjugates
Deonarain, M. P., & Xue, Q. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa024 · Cited by 33
Targeted Glioma Therapy—Clinical Trials and Future Directions
Shikalov, A. B., Koman, I. E., & Kogan, N. M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16010100 · Cited by 35
Opaliński, Ł., Sokołowska-Wędzina, A., Sochacka, M., Zakrzewska, M., & Otlewski, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-07479-z · Cited by 31
Aubrey, N., Allard-Vannier, É., Martin, C., Bryden, F., Letast, S., Colas, C., Lakhrif, Z., Collinet, N., Dimier‐Poisson, I., Chourpa, I., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00668 · Cited by 31
A “Dual” Cell-Level Systems PK-PD Model to Characterize the Bystander Effect of ADC
Singh, A. P., & Shah, D. K. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.01.034 · Cited by 31
Liang, Y., Li, S., Wang, X., He, B., He, B., Dai, W., Zhang, H., Wang, X., Wang, Y., Zhou, D., et al. (2017) · Theranostics · doi:10.7150/thno.20242 · Cited by 30
Marks, I. S., Gardeen, S. S., Kurdziel, S. J., Nicolaou, S. T., Woods, J. E., Kularatne, S. A., & Low, P. S. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00139 · Cited by 30
Molecular platforms for targeted drug delivery
Maso, K., Grigoletto, A., Vicent, M. J., & Pasut, G. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.03.001 · Cited by 30
Deneka, A. Y., Boumber, Y., Beck, T. N., & Golemis, E. A. (2019) · Cancers · doi:10.3390/cancers11091297 · Cited by 28
The target atlas for antibody-drug conjugates across solid cancers
Fang, J., Guo, L., Zhang, Y., Guo, Q., Wang, M., & Wang, X. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00701-3 · Cited by 26
Douez, E., Allard-Vannier, É., Amar, I. A. M., Jolivet, L., Boursin, F., Maisonial‐Besset, A., Witkowski, T., Chezal, J., Colas, C., Letast, S., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.01.012 · Cited by 24
Antibody–Drug Conjugates as an Emerging Therapy in Oncodermatology
Esnault, C., Schrama, D., Houben, R., Guyétant, S., Desgranges, A., Martin, C., Berthon, P., Viaud‐Massuard, M., Touzé, A., Kervarrec, T., et al. (2022) · Cancers · doi:10.3390/cancers14030778 · Cited by 24
Computational selection of antibody-drug conjugate targets for breast cancer
Fauteux, F., Hill, J. J., Jaramillo, M., Pan, Y., Phan, S., Famili, F. A., & O'Connor‐McCourt, M. D. (2015) · Oncotarget · doi:10.18632/oncotarget.6679 · Cited by 23
Cheung, C. H. P., Chong, T. H., Wei, T., Liu, H., & Li, X. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202217150 · Cited by 19
Miniaturised ‘antibody’-drug conjugates for solid tumours?
Deonarain, M. P. (2018) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2018.09.006 · Cited by 19
APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo
Staudacher, A. H., Li, Y., Liapis, V., Hou, J. J. C., Chin, D. Y., Dolezal, O., Adams, T. E., van Berkel, P. H., & Brown, M. P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0842 · Cited by 19
Deonarain, M. P., & Yahioglu, G. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1858050 · Cited by 18
β-Glucuronidase triggers extracellular MMAE release from an integrin-targeted conjugate
López, P., Müller, C., Breunig, C., Hechler, T., Pahl, A. M., Arosio, D., Belvisi, L., Pignataro, L., Corso, A. D., & Gennari, C. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00617f · Cited by 17
Acoustic disruption of tumor endothelium and on-demand drug delivery for cancer chemotherapy
Xu, J., Tu, H., Ao, Z., Chen, Y., Danehy, R., & Guo, F. (2019) · Nanotechnology · doi:10.1088/1361-6528/aafe4e · Cited by 16
Antibody drug conjugates: Development, characterization, and regulatory considerations
Kommineni, N., Pandi, P., Chella, N., Domb, A. J., & Khan, W. (2019) · Polymers for Advanced Technologies · doi:10.1002/pat.4789 · Cited by 16
Ling, Y.-Y., Ren, J. M., Li, T., Zhao, Y., & Wu, C. (2016) · Chemical Communications · doi:10.1039/c6cc00369a · Cited by 16
Zheng, Y., Shen, Y., Meng, X., Wu, Y., Zhao, Y., & Wu, C. (2019) · ChemMedChem · doi:10.1002/cmdc.201900248 · Cited by 16
Kim, S., Kim, H., Jo, D. H., Kim, J. H., Kim, S. R., Kang, D., Hwang, D., & Chung, J. (2018) · Methods · doi:10.1016/j.ymeth.2018.10.002 · Cited by 13
Drug Design of “Undruggable” Targets
Wang, J., Li, S., & Li, H. (2019) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201800552 · Cited by 13
Targeting the Phosphatidylserine-Immune Checkpoint with a Small-Molecule Maytansinoid Conjugate
Lo, C., Chiu, T., Liu, Y., Pan, P.-Y., Liu, K.-L., Hsu, C., Fang, M., Huang, Y., Yeh, T., Hsu, T., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00631 · Cited by 12
Contemporary Approaches to Immunotherapy of Solid Tumors
Kuznetsova, A. V., Glukhova, K. А., Попова, О. П., Beletsky, I. P., & Aa, I. (2024) · Cancers · doi:10.3390/cancers16122270 · Cited by 14
Jolivet, L., Amar, I. A. M., Horiot, C., Boursin, F., Colas, C., Letast, S., Denevault‐Sabourin, C., Allard-Vannier, É., Joubert, N., & Aubrey, N. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14081524 · Cited by 11
Antibody drug conjugates: the future of chemotherapy?
Borcoman, É., & Tourneau, C. L. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000310 · Cited by 11
Cheung, A., Liu, Y., Chenoweth, A. M., Montaseri, H., Esapa, B., Chudasama, V., Baker, J. R., Thurston, D. E., & Karagiannis, S. N. (2026) · Physiological Reviews · doi:10.1152/physrev.00039.2025 · Cited by 12
Mechanism of Action of AminoCBIs: Highly Reactive but Highly Cytotoxic Analogues of the Duocarmycins
Tercel, M., Pruijn, F. B., O'Connor, P. D., Liyanage, H. D. S., Atwell, G. J., & Alix, S. (2014) · ChemBioChem · doi:10.1002/cbic.201402256 · Cited by 9
Zhang, D., Guo, Y., Zhao, Y., Yu, L., Chang, Z., Pei, H., Huang, J., Chen, C., Xue, H., Xu, X., et al. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01559-6 · Cited by 8
Antibody–drug conjugates: targeted weapons against cancer
Scotti, C., Iamele, L., & Vecchia, L. (2015) · Antibody Technology Journal · doi:10.2147/anti.s52914 · Cited by 9
Emerging antibody-based therapies for the treatment of acute myeloid leukemia
Angenendt, L., Mikesch, J., & Schliemann, C. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102409 · Cited by 7
Angenendt, L., Reuter, S., Kentrup, D., Benk, A. S., Neumann, F., Hüve, J., Martens, A. C., Schwöppe, C., Keßler, T., Schmidt, L. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.208 · Cited by 7
Self-citationAntibody-Drug Conjugates: Targeting the Tumor Microenvironment
Corso, A. D., Cazzamalli, S., & Neri, D. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9_13 · Cited by 7
Self-citationSmall targeted cytotoxics from DNA-encoded chemical libraries
Samain, F., & Casi, G. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.02.009 · Cited by 6
Self-citationAntibody–Drug Conjugates: Empowering Antibodies for the Fight Against Cancer
Denevault‐Sabourin, C., Bryden, F., Viaud‐Massuard, M., & Joubert, N. (2019) · doi:10.1002/9783527814695.ch3 · Cited by 6
Metadata
- Authors
- Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D.
- Affiliations
- University of Lisbon (PT)
- Venue
- Cancer Research
- Published
- 2014-04-30
- Volume
- 74
- Issue
- 9
- Pages
- 2569-2578
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2073629335
- Cited by
- 130
- References
- 51
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 6 · 2023: 7 · 2022: 10 · 2021: 9 · 2020: 7 · 2019: 16 · 2018: 17 · 2017: 15 · 2016: 16 · 2015: 17 · 2014: 6
- FWCI
- 14.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Cambridge University Engineering Department Publications Database (submittedVersion)
- Funders
- Novartis Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Kommission für Technologie und Innovation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- antibody-drug conjugates, maytansinoids, DM1, fibronectin, tumor microenvironment, curative treatment, antigen uptake, extracellular matrix, tumor targeting, CT26 tumor, tissue distribution
- MeSH terms
- Animals, Antibodies, Antineoplastic Agents, Cricetulus, Female, Cricetinae, Humans, Maytansine, Mice, Inbred BALB C, Mice, Nude, Tissue Distribution, CHO Cells, Xenograft Model Antitumor Assays, Cell Line, Tumor, Mice, Embryonal Carcinoma Stem Cells, Mice, 129 Strain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
